Alnylam Pharmaceuticals

Update in progress

ALNY (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Alnylam Pharmaceuticals discovers, develops, manufactures, and commercializes RNA interference therapeutics globally. Its marketed products include ONPATTRO for hATTR amyloidosis, AMVUTTRA for ATTR and hATTR, Leqvio for hypercholesterolemia, Qfitlia for hemophilia A or B, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1. The company also has Phase 1–3 programs and collaborations with Regeneron, Roche, Sanofi, Novartis, and others. Founded 2002, Cambridge, MA.

Company score

Sentiment: 1.07; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.25; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.88; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.20; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.39; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.73; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive